Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Citizen Petition Proposed Rule Would Have Minimal Device Center Impact

This article was originally published in The Gray Sheet

Executive Summary

FDA's proposed rule winnowing actions that can be requested by citizen petitions is unlikely to have a significant impact on the Center for Devices and Radiological Health, staffers report. While the reg likely would cut down on the number of petitions filed, officials point out that the center has neither a backlog nor a persistent problem with "nuisance" petitions.

You may also be interested in...

Regulatory News In Brief

HHS issues conflict of interest draft guidance: "1Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human Subject Protection" recommends taking measures such as separating responsibility for financial and research decisions and establishing CoI committees to verify the absence of financial interests. Aimed at individuals and organizations engaged in human subjects research, the March 31 guidance provides points to consider and aligns with December 2001 GAO recommendations calling on HHS to develop best practices for managing investigator and institutional financial CoI in biomedical research. Comments on the guidance are due by May 30...

Teva Plans To Appeal EU Provigil Fine

Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts